PET/MR biomarkers guide personalized treatment for patients with pancreatic cancer

Researchers from the Mayo Clinic have found that PET/MR can help guide post- neoadjuvant therapy (NAT) pancreatic cancer treatment decisions to optimize treatment decisions and long-term outcomes⁶. The study, recently published in the American Journal of Roentgenology, assessed pathologic tumor response to emergent pancreatic cancer therapies and predicted overall survival using PET/MR and CT data.

The authors wrote that PET/MR provides a non-invasive selection tool to help clinicians decide if surgery will benefit the patient, and if alternate treatment regimens could optimize a patient’s chances for favorable long-term outcomes. They concluded that PET/ MR’s potential in pancreatic cancer provides clinicians with a clearer picture of the therapies’ efficacy and can guide next steps, potentially allowing specialists to tailor care to each patient’s disease profile.